Thursday, 18 May 2017

Clinical Studies of Niraparib

The drug was evaluated in clinical studies involving 553 people with any of these recurring cancers who had had their tumors shrunk by at least two doses of platinum-based chemotherapy. The average progression-free survival of certain women given Niraparib was 21 months, compared with 5.5 months among women who took a placebo, the FDA said.

No comments:

Post a Comment